Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) Short Interest Down 45.5% in May

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report) was the recipient of a large drop in short interest during the month of May. As of May 29th, there was short interest totaling 225,427 shares, a drop of 45.5% from the May 14th total of 413,714 shares. Based on an average trading volume of 760,388 shares, the short-interest ratio is presently 0.3 days. Currently, 0.0% of the company’s shares are short sold.

Coloplast A/S Stock Performance

Coloplast A/S stock opened at $5.99 on Monday. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.30 and a quick ratio of 0.81. Coloplast A/S has a 1-year low of $5.83 and a 1-year high of $10.03. The firm has a market capitalization of $13.50 billion, a P/E ratio of 42.79, a price-to-earnings-growth ratio of 1.90 and a beta of 0.18. The company’s 50-day moving average is $6.38 and its 200 day moving average is $7.48.

Get Coloplast A/S alerts:

Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.01. Coloplast A/S had a net margin of 7.46% and a return on equity of 31.96%. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.11 billion. Research analysts forecast that Coloplast A/S will post 0.4 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CLPBY. The Goldman Sachs Group downgraded shares of Coloplast A/S from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 7th. Kepler Capital Markets raised shares of Coloplast A/S to a “strong-buy” rating in a report on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Coloplast A/S currently has an average rating of “Hold”.

Read Our Latest Research Report on Coloplast A/S

About Coloplast A/S

(Get Free Report)

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.

Featured Stories

• Five stocks we like better than Coloplast A/S
• 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
• What to Expect From Q2 Earnings as Tech Strength Broadens
• Viasat’s Orbiting Profits: Space Force Jackpot?
• Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters

Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.